Michael Makris/LinkedIn
Mar 2, 2026, 13:42
Michael Makris: How Early Can Hemlibra Be Started?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Eman Hassan et al, published in RPTH Journal:
”How early can you start Hemlibra (emicizumab)?
A paper in the RPTH Journal describes its effective use when started at 26 hours of age, in a baby with hemophilia born 10 weeks premature (at 30 weeks of gestation).”
Title: Emicizumab Prophylaxis in a Preterm Infant with Severe Haemophilia A: A Case Report on the Feasibility of Early Use
Authors: Eman Hassan, Charles Percy, Amna Ahmed, Gillian Lowe, Will Lester, Neil V. Morgan, Jayashree Motwani
Read the Full Article on RPTH Journal․
Other articles featuring Michael Makris on Hemostasis Today.
-
Mar 2, 2026, 13:39Platelets Journal Welcomes Sarah Westbury as Principal Editor to the Editorial Board
-
Mar 2, 2026, 11:10AbQader Bedil: A Practical Diagnostic Workflow for Von Willebrand Disease
-
Mar 2, 2026, 11:06Advancing Visibility, Research, and Equitable Care on Rare Disease Day – WFH
-
Mar 2, 2026, 11:02Jecko Thachil: Exploring the Origins and Meaning of the Term Hemophilia
-
Mar 2, 2026, 10:56Emmanuel J Favaloro: The Most Popular Downloaded Papers in 2025 from Seminars in Thrombosis and Hemostasis
-
Mar 2, 2026, 10:48Akinchan Bhardwaj: Key Genomic Insights Transforming Coronary Artery Disease Prevention
-
Mar 2, 2026, 08:07Michael Makris: Exploring ADAMTS13, vWF Imbalance, and Endotheliopathy in Ischemic Stroke
-
Mar 2, 2026, 07:31Thrombocytopenia in Tropical Infectious Diseases – RPTH Journal
-
Mar 1, 2026, 13:17Michael Makris։ Extraterrestrial Regolith as a Trigger of the Intrinsic Coagulation Pathway